COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia - PubMed (original) (raw)
. 2007 Feb;90(1-3):86-96.
doi: 10.1016/j.schres.2006.10.002. Epub 2006 Nov 22.
Affiliations
- PMID: 17123785
- DOI: 10.1016/j.schres.2006.10.002
COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia
Neil D Woodward et al. Schizophr Res. 2007 Feb.
Abstract
Preliminary evidence suggests that a single nucleotide polymorphism (SNP), the val108/158met SNP, within the gene that codes for catechol-O-methyltransferase (COMT), a key enzyme involved in regulating dopamine (DA) transmission within the prefrontal cortex (PFC), is related to cognitive function in schizophrenia and cognitive improvement with atypical antipsychotic drugs (APDs). Specifically, several studies have identified an association between working memory and executive functions, and COMT val108/158met genotype in schizophrenia; although there have been several negative findings that are likely related to small sample sizes and, possibly, medication status of patients at the time of testing. The association between COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine was investigated in a relatively large prospective sample of patients with schizophrenia, most of whom were unmedicated at baseline. Patients were genotyped for the COMT val108/158met SNP after completing a cognitive battery consisting of tests of attention, working memory, verbal learning and memory, executive function, and verbal fluency at baseline and after 6 weeks and 6 months of treatment with clozapine. Consistent with several previous studies, an association between COMT genotype and tests of executive function and working memory was identified at baseline. In addition, a novel interaction between genotype and improvement on tests of attention and verbal fluency was identified. Specifically, met homozygous and val/met heterozygous patients demonstrated significantly greater improvement than val homozygous patients following 6 months of treatment with clozapine. The results are discussed in relation to previous cross-sectional studies and prospective investigations of the associations between COMT genotype, cognition, and cognitive improvement with atypical APDs in schizophrenia.
Similar articles
- Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications.
Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, Weinberger DR. Weickert TW, et al. Biol Psychiatry. 2004 Nov 1;56(9):677-82. doi: 10.1016/j.biopsych.2004.08.012. Biol Psychiatry. 2004. PMID: 15522252 Clinical Trial. - Catechol O-methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls.
Wirgenes KV, Djurovic S, Sundet K, Agartz I, Mattingsdal M, Athanasiu L, Melle I, Andreassen OA. Wirgenes KV, et al. Schizophr Res. 2010 Sep;122(1-3):31-7. doi: 10.1016/j.schres.2010.05.007. Epub 2010 Jun 1. Schizophr Res. 2010. PMID: 20605701 - Catechol-O-methyl transferase and schizophrenia.
Sagud M, Mück-Seler D, Mihaljević-Peles A, Vuksan-Cusa B, Zivković M, Jakovljević M, Pivac N. Sagud M, et al. Psychiatr Danub. 2010 Jun;22(2):270-4. Psychiatr Danub. 2010. PMID: 20562760 Review. - Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test.
Opgen-Rhein C, Neuhaus AH, Urbanek C, Hahn E, Sander T, Dettling M. Opgen-Rhein C, et al. Schizophr Bull. 2008 Nov;34(6):1231-9. doi: 10.1093/schbul/sbm155. Epub 2008 Jan 16. Schizophr Bull. 2008. PMID: 18199630 Free PMC article. - The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
Meltzer HY, McGurk SR. Meltzer HY, et al. Schizophr Bull. 1999;25(2):233-55. doi: 10.1093/oxfordjournals.schbul.a033376. Schizophr Bull. 1999. PMID: 10416729 Review.
Cited by
- Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics.
Zubiaur P, Fernández-Campos P, Navares-Gómez M, Soria-Chacartegui P, Villapalos-García G, Román M, Mejía-Abril G, Ochoa D, Abad-Santos F. Zubiaur P, et al. Pharmaceutics. 2021 Sep 28;13(10):1573. doi: 10.3390/pharmaceutics13101573. Pharmaceutics. 2021. PMID: 34683865 Free PMC article. - Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
Arranz MJ, Kapur S. Arranz MJ, et al. Schizophr Bull. 2008 Nov;34(6):1130-44. doi: 10.1093/schbul/sbn114. Epub 2008 Aug 27. Schizophr Bull. 2008. PMID: 18753306 Free PMC article. Review. - Theranostic Biomarkers for Schizophrenia.
Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Perkovic MN, et al. Int J Mol Sci. 2017 Mar 30;18(4):733. doi: 10.3390/ijms18040733. Int J Mol Sci. 2017. PMID: 28358316 Free PMC article. Review. - Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.
Shad MU. Shad MU. Behav Sci (Basel). 2021 Jun 30;11(7):97. doi: 10.3390/bs11070097. Behav Sci (Basel). 2021. PMID: 34209185 Free PMC article. Review. - Effect of second-generation antipsychotics on cognition: current issues and future challenges.
Hill SK, Bishop JR, Palumbo D, Sweeney JA. Hill SK, et al. Expert Rev Neurother. 2010 Jan;10(1):43-57. doi: 10.1586/ern.09.143. Expert Rev Neurother. 2010. PMID: 20021320 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous